Efficacy and safety of dual combination therapy of blood pressure-lowering drugs as initial treatment for hypertension: a systematic review and meta-analysis of randomized controlled trials.

Abstract

OBJECTIVE\nTo assess the efficacy and tolerability of dual combination of blood pressure (BP)-lowering drugs as initial treatment for hypertension.\n\n\nMETHODS\nMEDLINE, Embase, CENTRAL were searched until August 2017 for randomized, double-blind trials of dual combination therapy vs. monotherapy in adults with hypertension who were either treatment naïve or untreated for at least 4 weeks. Regimens were classified with reference to usual daily standard-dose ; for example, <1\u200a+\u200a<1 for a combination of two drugs both at less than one standard-dose. Random-effects models were used for meta-analysis.\n\n\nRESULTS\nThirty-three trials (13\u200a095 participants) with mean baseline mean BP 155/100\u200ammHg were included. Compared with standard-dose monotherapy, dual combinations of <1\u200a+\u200a<1, 1\u200a+\u200a<1 and 1\u200a+\u200a1 (i.e. low-to-standard dose), showed a dose-response relationship in reducing SBP [mean differences (95% confidence interval) of 2.8 (1.6-4.0), 4.6 (3.4-5.7) and 7.5 (5.4-9.5)\u200ammHg, respectively], and in improving BP control [risk ratio (RR) (95% confidence interval) 1.11 (0.92-1.34), 1.25 (1.16-1.35) and 1.42 (1.27-1.58), respectively]. Withdrawals due to adverse events were uncommon with low-to-standard dose dual combinations, with no significant difference compared with standard-dose monotherapy [2.9 vs. 2.2%; RR 1.28 (0.85 to 1.92)]. There were fewer data for higher dose dual combinations, which did not appear to produce substantial additional efficacy and could potentially be less tolerable.\n\n\nCONCLUSION\nCompared with standard-dose monotherapy, initiating treatment with low-to-standard dose dual combination therapy is more efficacious without increasing withdrawals due to adverse events.\n\n\nPROSPERO REGISTRATION\nCRD42016032822.